Glycogen synthase kinase 3: a point of integration in Alzheimer's disease and a therapeutic target?
Glycogen synthase kinase 3 (GSK3) has been implicated in neurological disorders; therefore, it is not surprising that there has been an increased focus towards developing therapies directed to this kinase. Unfortunately, these current therapies have not taken into consideration the physiological role of GSK3 in crucial events like synaptic plasticity. With this in mind we will discuss the relationship of synaptic plasticity with GSK3 and tau protein and their role as potential targets for the development of therapeutic strategies. Finally, we will provide perspectives in developing a cocktail therapy for Alzheimer's treatment.
Department of Psychiatry, Douglas Hospital Research Center, McGill University, Montreal, QC, Canada H4H 1R3.
Siddhartha
S
Mondragón-Rodríguez
George
G
Perry
Xiongwei
X
Zhu
Paula I
PI
Moreira
Sylvain
S
Williams